Hongfu D. Cai
China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications
Correction: Comparison of treatment patterns, efficacy and safety between generic and branded Atorvastatin users in China: a multicenter, retrospective propensity score‑matched cohort study.
Journal: Lipids in health and disease
Published: October 24, 2025
Cost-Effectiveness of De Novo Combination of Tenofovir Alafenamide Fumarate and Peginterferon Alfa-2b Versus Peginterferon Alfa-2b Monotherapy of HBeAg-Positive Chronic Hepatitis B in China.
Journal: Journal of viral hepatitis
Published: October 10, 2025
Comparative safety analysis of enfortumab vedotin and pembrolizumab: monotherapy vs. combination therapy insights from FDA adverse event reporting system data.
Journal: World journal of urology
Published: September 29, 2025
Updated cost-effectiveness analysis of first-line novel therapies in locally advanced or metastatic urothelial carcinoma across the UK, US, and China.
Journal: World journal of urology
Published: May 23, 2025
Comparison of treatment patterns, efficacy and safety between generic and branded atorvastatin users in China: a multicenter, retrospective propensity score-matched cohort study.
Journal: Lipids in health and disease
Published: January 10, 2025
Cost-effectiveness of sequential treatment strategies involving first-line pembrolizumab with trastuzumab and chemotherapy for unresectable metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Journal: Therapeutic advances in medical oncology
Published: January 02, 2025
Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States.
Journal: Therapeutic advances in medical oncology
Published: December 27, 2024
Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.
Journal: BMJ open
Published: December 11, 2024
Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer.
Journal: Scientific reports
Published: August 27, 2024
Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis.
Journal: Frontiers in pharmacology
Published: August 05, 2024
Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: July 09, 2024
Cost-effectiveness of nivolumab combined with chemotherapy as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma.
Journal: Therapeutic advances in medical oncology
Published: July 09, 2024
Last Updated: 09/26/2026